Skip to main content

Advertisement

Table 3 Mean and SEM values for the monitored diabetes-related parameters Hb1Ac, glucose and insulin in blood from the NHPs at baseline and during treatment with the omega-3 rich phospholipids. Dose levels of administered phospholipids, EPA, DHA and choline are given at the end of the table

From: Effects of a purified krill oil phospholipid rich in long-chain omega-3 fatty acids on cardiovascular disease risk factors in non-human primates with naturally occurring diabetes type-2 and dyslipidemia

Parameter Group Value Baseline Week after start of treatment
2 4 6 8 10 12
Hb1Ac (%) Control Mean 9.07 8.60 9.00 9.00 9.37 9.43 9.80
SEM 2.31 2.05 2.35 2.40 2.56 2.69 2.87
Treated Mean 6.63 6.53 6.50 6.40 6.50 6.40 6.67
SEM 1.43 1.64 1.46 1.37 1.23 1.48 1.49
Glucose (mg(dL) Control Mean 195 197 196 182 177 181 203
SEM 64.1 71.8 62.0 61.4 65.8 64.5 71.9
Treated Mean 148 135 157 127 158 119 141
SEM 41.2 31.7 38.3 35.5 30.0 20.0 32.3
Insulin (mIU/mL) Control Mean 33.1 26.3 21.9 46.2 20.9 21.8 28.1
SEM 5.27 5.32 4.86 21.28 5.51 5.61 10.5
Treated Mean 66.7 112 104 91.6 115 74.2 96.7
SEM 29.6 52.1 44.3 40.7 60.5 29.0 54.1
Dose (mg phospholipids/kg bw/day) 50 150 450
Dose (mg [EPA/DHA]/kg bw/day) 9,35/5,48 28,1/16,4 84.2/49.3
Dose (mg choline/kg bw/day) 5,83 17,5 52,5